此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of aMMP-8 and IL-1β Levels and Marginal Bone Loss Associated With Peri-Implant Mucositis and Peri-Implantitis in Postmenopausal Women

2026年8月21日 更新者:Emrah Turkmen、Medipol University

Peri-implant mucositis and peri-implantitis are among the major biological complications threatening the long-term success of dental implants. Current diagnostic approaches are primarily based on clinical and radiographic assessments; however, there is still a need for reliable biomarkers that can detect biological alterations before extensive tissue destruction occurs. Hormonal changes associated with the postmenopausal period may influence bone metabolism and inflammatory responses, thereby increasing the susceptibility of peri-implant tissues to disease. Nevertheless, studies investigating local inflammatory biomarkers in peri-implant diseases among postmenopausal women remain limited.

Active matrix metalloproteinase-8 (aMMP-8) is a key enzyme involved in collagen degradation and connective tissue destruction and is considered one of the most important biomarkers of periodontal and peri-implant tissue breakdown. Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine associated with inflammatory responses, bone resorption, and tissue destruction. Assessment of these biomarkers in peri-implant crevicular fluid may contribute to the early diagnosis and risk assessment of peri-implant diseases.

The aim of this project is to evaluate the association between peri-implant health, peri-implant mucositis, peri-implantitis, and peri-implant crevicular fluid levels of aMMP-8 and IL-1β in postmenopausal women, together with clinical and radiographic parameters. Postmenopausal women with at least one functional dental implant will be recruited and classified into three groups according to their peri-implant status. Clinical peri-implant parameters will be recorded, standardized radiographic examinations will be performed, and peri-implant crevicular fluid samples will be collected using the PerioPaper method. Levels of aMMP-8 and IL-1β will be quantified using enzyme-linked immunosorbent assay (ELISA).

The obtained data will be analyzed using advanced statistical methods to investigate the relationships between biomarker levels and clinical and radiographic disease parameters. In addition, the diagnostic performance of aMMP-8 and IL-1β for distinguishing peri-implantitis will be evaluated using receiver operating characteristic (ROC) analyses, and potential threshold values will be explored. The project is expected to provide novel insights into the role of local inflammatory biomarkers in peri-implant diseases among postmenopausal women, contribute to the identification of high-risk individuals, and support the development of personalized preventive and therapeutic strategies.

研究概览

研究类型

观察性的

注册 (估计的)

120

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

Postmenopausal women aged 45-70 years with at least one functional dental implant will be recruited from patients attending the Periodontology Clinic. Participants will be classified according to their peri-implant clinical and radiographic status as peri-implant health, peri-implant mucositis, or peri-implantitis.

描述

Inclusion Criteria:

  • Postmenopausal status, defined as amenorrhea for at least 12 months
  • Aged 45-70 years
  • Presence of at least one functional dental implant
  • Completed and functional implant-supported prosthetic restoration
  • Implant in function for at least 1 year after prosthetic loading
  • No systemic or local condition preventing clinical or radiographic assessment
  • Provision of written informed consent

Exclusion Criteria:

  • Current smoking
  • Presence of uncontrolled systemic disease
  • Use of antibiotics or anti-inflammatory medications within the past 3 months
  • Periodontal or peri-implant surgical treatment within the past 6 months
  • History of radiotherapy to the head and neck region or chemotherapy
  • Any condition preventing reliable clinical, radiographic, or biochemical assessment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Postmenopausal Peri-implant Health
Postmenopausal women with healthy peri-implant tissues, without clinical signs of inflammation or pathological bone loss.
Postmenopausal Peri-implant mucositis
Postmenopausal women with peri-implant soft tissue inflammation without progressive bone loss.
Postmenopausal Peri-implantitis
Postmenopausal women with peri-implant inflammation and progressive supporting bone loss.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
IL-1B levels
大体时间:baseline
Saliva and Peri-implant Sulcular Fluid Interleukin-1B (IL-1b) Levels measured by ELISA
baseline
aMMP-8 levels
大体时间:baseline
Saliva and Peri-implant Sulcular Fluid active-Matrix Metalloproteinase-8 (aMMP-8) Levels measured by ELISA
baseline
Marginal bone loss
大体时间:baseline
Marginal bone levels will be measured mesially and distally on standardized periapical radiographs using a fixed implant reference point.
baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月19日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2027年2月1日

研究注册日期

首次提交

2026年8月21日

首先提交符合 QC 标准的

2026年8月21日

首次发布 (实际的)

2026年8月25日

研究记录更新

最后更新发布 (实际的)

2026年8月25日

上次提交的符合 QC 标准的更新

2026年8月21日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • 335

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅